Terazosin was approved by the Food and Drug Administration (FDA) in 1987 initially as a treatment for hypertension.

Off-labelÂ uses for terazosin currently being studied include the following:

- In more recent literature, terazosin, among other agents of its class been the subject of research as an off-label agent for the use of medical expulsive therapy (MET), a form of medical management for distal ureteral calculi.

- Alleviation of nightmares associated with post-traumatic stress disorder (PTSD)

- Antihidrotic in patients who have hyperhidrosis related to selective serotonin reuptake inhibitor (SSRI) use

- Chronic prostatitis/chronic pelvic pain syndrome

- Urethritis associated with radiation therapy

- Idiopathic oligozoospermia